DYNAMICS OF LEUKOCYTIC INFLAMMATORY MARKERS AND COLCHICINE ROLE AS ANTI-INFLAMMATORY THERAPY IN ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION

Abstract

The aim of the study – to assess the dynamics of leukocytic inflammation markers inpatients with ST-segment elevation myocardial infarction (STEMI) when prescribedcolchicine as a part of optimal medical therapy (OMT).Materials and methods. To achieve the stated goal, 24 patients with STEMI undergoinginpatient treatment were examined. Group 1 (n = 12) consisted of patients with STEMIreceiving traditional OMT, while Group 2 comprised STEMI patients who were prescribedcolchicine (0.5 mg once a day) in combination with OMT. General clinical blood analysiswas used to evaluate inflammatory markers upon admission to the hospital and on the30th day of treatment. Hematological markers included: 1) neutrophil-to-lymphocyteratio (NLR); 2) platelet-to-lymphocyte ratio (PLR); 3) systemic immune inflammationindex (SII).Results. Assessing the parameters of the general blood analysis during the treatmentdynamics in Group 2 patients revealed a significant decrease in the peripheral blood leukocytelevel 38.29 % (p<0.01), neutrophils 57.91 % (p<0.01), monocytes 28.16 % (p<0.01),while patients in Group 1 did not show significant differences in treatment dynamics. Group 2 patients demonstrated a probable increase in lymphocyte count 35.26 % (p<0.01),with no significant dynamics observed in Group 1 patients. No probable dynamics wereobserved regarding changes in platelet levels in either of the STEMI patient groups.Evaluation of leukocytic inflammatory markers during the prescribed treatment in Group2 patients showed a reduction in NLR 68.36 % and SII 67.69 % (p<0.01). There wasno probable difference in PLR index after treatment in Group 2 patients. In Group 1patients, there was a tendency towards an increase in NLR 21.90 % (p>0.05), SII 23.51 %(p>0.05), and PLR 35.12 % (p>0.05) compared to baseline data.Conclusions. Additional administration of colchicine at a dose of 0.5 mg once daily for 30days to patients with ST-segment elevation myocardial infarction, in addition to optimalmedical therapy, likely contributes to a reduction in leukocytic inflammatory markers,specifically neutrophil-to-lymphocyte ratio (p<0.01) and systemic immune inflammationindex (p<0.01), reflecting the inflammatory response after STEMI.